Pre-Market Earnings Report for November 28, 2025 : CHA

Chagee Holdings (CHA) is scheduled to report results for the quarter ended September 30, 2025, prior to the market open on 11/28/2025; consensus EPS from two analysts is $0.40, representing a 99.96% year‑over‑year decline. Zacks cites a 2025 P/E of 9.04 for CHA versus an industry ratio of -9.70, implying relatively stronger earnings prospects despite the near-total EPS drop; limited analyst coverage and the magnitude of the decline suggest heightened risk and warrant caution for investors.

Analysis

Market structure: A near-100% year-over-year EPS drop for CHA (consensus $0.40) makes CHA a direct loser — market-share and shelf space will likely flow to national beverage incumbents (KO, PEP) and better-capitalized regional tea brands over 1–4 quarters. Pricing power for CHA is impaired; expect trade promotions and channel discounting to preserve volumes, pressuring margins by 200–500bps near-term. Cross-asset impacts are idiosyncratic: CHA’s equity will see IV spike around 11/28, limited corporate bond/FX ripple unless multiple Chinese microcaps report similar shocks.

Risk assessment: Tail risks include creditor covenant breaches, delisting or regulatory action in China (low-probability, high-impact) and a USD/CNY move that magnifies reporting weakness; plan for binary outcomes around the 11/28 EPS print and 30–90 day post-release liquidity. Immediate (days) risk is an IV squeeze and big gap; short-term (weeks) risk is accelerated downgrades and distributor bad-debt recognition; long-term (quarters) depends on restructuring or capital raise. Hidden dependencies: concentrated distributor/customer exposure and one-off accounting items can distort EPS — verify 10-Q/MD&A and days-sales-outstanding within 48 hours.

Trade implications: If borrow is available, establish a 2–3% portfolio short in CHA or buy 6–8 week put options (5–15% OTM) sized to risk no more than 0.5% portfolio loss if trade goes against you; target 30–50% downside within 2–6 weeks if miss. Pair trade: short CHA and go long KO or PEP equal notional (ticker KO, PEP) to neutralize beverage margin cyclicality; reduce microcap Chinese beverage exposure by 25–50% and increase staples by 2–4% allocation. If implied vol >40% pre-earnings, favor short equity + long-tail puts; if IV is low (<25%), buy a straddle/strangle around earnings.

Contrarian angles: With only two analysts, consensus may reflect stale models — EPS collapse may be driven by one-time, non-cash items, capping downside if cleaned up in subsequent quarters; conversely, illiquidity and low float can produce sharp jumps (short squeeze). Historical parallels (small-cap China restructurings) show steep intraday drops followed by 30–70% recoveries over 6–12 months if management executes a credible turnaround. Action: post-meltdown, consider a 0.5–1% option-based long (6–12 month OTM call spread) if governance improvements or a credible cash-infusion is announced.

Key Decisions for Investors

• Establish a targeted short position in CHA equal to 2–3% of portfolio notional (or buy 6–8 week puts 5–15% OTM) before the 11/28 earnings print; use a hard stop-loss at 15–20% adverse move and target a 30–50% profit within 2–6 weeks if the company misses or guidance is cut.
• Implement a pair trade: short CHA and simultaneously add an equal-dollar long in KO or PEP (tickers KO, PEP) sized 1–2% of portfolio to capture idiosyncratic downside while maintaining sector exposure; rebalance after earnings and cut the pair if CHA announces verified one-off adjustments within 7 days.
• Reduce direct exposure to microcap Chinese beverage names by 25–50% over the next 30 days and redeploy 2–4% into US staples (KO, PEP) for defensive carry; increase cash/government bills by 1–2% to fund volatility-driven entry opportunities.
• If CHA stock gaps down >30% on 11/28 and governance/cash posture remains unclear, initiate a speculative 0.5–1% position via a 6–12 month OTM call spread (buy call 30–50% OTM, sell call 70–100% OTM) as a recovery asymmetric play contingent on announced restructuring or capital injection within 90 days.